Associated Papers
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
30206299 (PubMed )
Supplement: 41397_2018_44_MOESM5_ESM.xlsx › Sheet1
Identification and functional characterization of novel nonsynonymous variants in the human multidrug and toxin extrusion 2-K.
Nishimura K et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics.
Chung JY et al.
Pharmacogenetics and Genomics, 2013
The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
Stocker SL et al.
Clinical Pharmacology and Therapeutics, 2013
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
Mannino GC et al.
Molecular Diagnosis & Therapy, 2012
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
A common 5'-UTR variant in MATE2-K is associated with poor response to metformin.
Choi JH et al.
Clinical Pharmacology and Therapeutics, 2011
Select a paper to view details